BTIG Maintains Buy on AVITA Medical, Raises Price Target to $15
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $11 to $15.